RKLB
Rocket Lab USA, Inc.
RKLB offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
RXO
RXO, Inc.
RXO has a slight edge over RKLB overall, supported by lower modeled downside.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
RXO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Weak |
RXO's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
RXO PE Valuation
RXO has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 54x next year's earnings.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
RXO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect RXO to return to profit, with revenue growing. However, they disagree widely on these estimates.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
RXO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.52 | — |
| Q3 2026 | -$0.52 | -$0.04 |
| Q2 2026 | -$0.62 | +$1.59 |
| Q1 2026 | -$0.62 | +$1.60 |
| Q4 2025 | -$0.59 | +$1.58 |
| Q3 2025 | -$0.48 | +$1.51 |
| Q2 2025 | -$2.21 | -$2.02 |
| Q1 2025 | -$2.22 | -$2.12 |
| Q4 2024 | -$2.17 | -7333% |
RXO is still losing money, but far less than before: $0.52 per share over the past year, against $2.22 at its worst in early 2025.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over RXO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
RXO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +32% |
| Q2 2026 | $1.8B | +25% |
| Q1 2026 | $1.4B | -0.6% |
| Q4 2025 | $1.5B | -12% |
| Q3 2025 | $1.4B | +37% |
| Q2 2025 | $1.4B | +53% |
| Q1 2025 | $1.4B | +57% |
| Q4 2024 | $1.7B | +70% |
RXO's revenue is growing: $1.9B last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.9% | +1.4 points |
| Q2 2026 | 0.1% | +0.1 points |
| Q1 2026 | -2% | +0.1 points |
| Q4 2025 | -2.9% | -1.4 points |
| Q3 2025 | -0.5% | +1.4 points |
| Q2 2025 | 0% | 0 points |
| Q1 2025 | -2.1% | -0.8 points |
| Q4 2024 | -1.4% | -2.9 points |
RXO has the edge over RKLB on profitability, with a higher operating margin.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
RXO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12M | +33% |
| Q2 2026 | -$52M | -678% |
| Q1 2026 | -$24M | -$7M |
| Q4 2025 | -$9M | +$10M |
| Q3 2025 | $9M | +$27M |
| Q2 2025 | $9M | +$25M |
| Q1 2025 | -$17M | -$13M |
| Q4 2024 | -$19M | -2000% |
RXO has the edge over RKLB on cash flow, with more consistent year-over-year improvement.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RXO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +2.4M shares |
| 1 year | +2% | +3.4M shares |
| 3 years | +47% | +55M shares |
| 5 years | +49% | +56.9M shares |
RXO has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RXO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.4x | High |
| Q2 2026 | 16.0x | High |
| Q1 2026 | 12.9x | High |
| Q4 2025 | 10.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 9.2x | High |
| Q1 2025 | 13.4x | High |
| Q4 2024 | 10.7x | High |
RXO's net debt is about 8.4 years of its operating earnings (EBITDA), up from 6.3 years a year ago.
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
RXO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.7 | Neutral |
| Stochastic | 85.5 | Overbought |
RXO's weekly RSI is 61 (neutral) and its Stochastic is 85 (overbought).
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
RXO PE vs Industrials Sector
| Metric | RXO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
RXO has no meaningful PE right now: it lost money over the past year.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB's trend is mixed: it's above three of its five weekly moving averages, and 104% above its 200-week average.
RXO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.6 | 6.3% above |
| 20 week MA | $24.6 | 15% above |
| 50 week MA | $20.4 | 38% above |
| 100 week MA | $18.9 | 49% above |
| 200 week MA | $20.6 | 37% above |
RXO has the edge over RKLB on trend strength, trading above more of its moving averages.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB's yearly returns have swung widely, from +392% in 2024 to −69% in 2022. It's down 9.3% so far in 2026.
RXO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $21.5 | $16.3 | -24% |
| 2023 | $16.3 | $23.3 | +43% |
| 2024 | $23.3 | $24.4 | +4.7% |
| 2025 | $24.4 | $12.7 | -48% |
| 2026 YTD | $12.7 | $28.3 | +123% |
RXO has the edge over RKLB on returns for 2026, with the stronger performance.